Pharmacological effect of a new idebenone formulation in a model of carrageenan-induced inflammatory pain

Pharmacological Research

Volumn 111, Issue , 2016, Pages 763-767

  Lauro, Filomena ^a   Ilari, Sara ^a   Giancotti, Luigino Antonio ^a   Ventura, Cinzia Anna ^b   Morabito, Chiara ^c   Gliozzi, Micaela ^d   Malafoglia, Valentina ^e   Palma, Ernesto ^d   Paolino, Donatella ^d   Mollace, Vincenzo ^d   Muscoli, Carolina ^d  

^a IRCCS San Raffaele   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^e Institute for Research on Pain   (Italy)

Author keywords

Antioxidant; HP cyclodextrins; Idebenone; Inflammatory pain; Oxidative stress

Indexed keywords

ALPHA CYCLODEXTRIN; IDEBENONE; MANGANESE SUPEROXIDE DISMUTASE; 2 HYDROXYPROPYL BETA CYCLODEXTRIN; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; CARRAGEENAN; MALONALDEHYDE; SUPEROXIDE DISMUTASE; UBIQUINONE;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; HIND PAW; HYPERALGESIA; INFLAMMATORY PAIN; LIPID PEROXIDATION; MALE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PAW EDEMA; PRIORITY JOURNAL; RAT; ROTAROD TEST; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG FORMULATION; EDEMA; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY; SPINAL CORD; SPRAGUE DAWLEY RAT; TIME FACTOR;

2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CARRAGEENAN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMPOUNDING; EDEMA; HYPERALGESIA; INFLAMMATION; MALE; MALONDIALDEHYDE; OXIDATIVE STRESS; RATS, SPRAGUE-DAWLEY; SPINAL CORD; SUPEROXIDE DISMUTASE; TIME FACTORS; UBIQUINONE;

EID: 84980463782     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.07.043     Document Type: Article

References (51)

1. [1] Nathan, C., Ding, A., Non resolving inflammation. Cell 140 (2010), 871–882.
2. [2] Sugimoto, M.A., Sousa, L.P., Pinho, V., Perretti, M., Teixeira, M.M., Resolution of inflammation: what controls its onset?. Front. Immunol. 26 (2016), 7–160.
3. [3] Wall, P.D., Melzack, R., Textbook of Pain. 2000, Churchill Livingstone, Edinburgh.
4. [4] Muley, M.M., Krustev, E., McDougall, J.J., Preclinical assessment of inflammatory pain. CNS Neurosci Ther 22 (2016), 88–101.
5. [5] Watkins, L.R., Milligan, E.D., Maier, S.F., Spinal cord glia: new players in pain. Pain 93 (2001), 201–205.
6. [6] Salvemini, D., Doyle, T., Kress, M., Nicol, G., Therapeutic targeting of the ceramide-to-sphingosine 1-phosphate pathway in pain. Trends Pharmacol. Sci. 34 (2013), 110–118.
7. [7] Salvemini, D., Neumann, W.L., Peroxynitrite: a strategic linchpin of opioid analgesic tolerance. Trends Pharmacol. Sci. 30 (2009), 194–202.
8. [8] Salvemini, D., Neumann, W., Targeting peroxynitrite driven nitroxidative stress with synzymes: a novel therapeutic approach in chronic pain management. Life Sci. 86 (2010), 604–614.
9. [9] Muscoli, C., Dagostino, C., Ilari, S., Lauro, F., Gliozzi, M., Bardhi, E., et al. Posttranslational nitration of tyrosine residues modulates glutamate transmission and contributes to N-methyl-D-aspartate-mediated thermal hyperalgesia. Mediator Infiamm. 2013 (2013), 950–994.
10. [10] Muscoli, C., Cuzzocrea, S., Ndengele, M.M., Mollace, V., Porreca, F., Fabrizi, F., et al. Therapeutic manipulation of peroxynitrite attenuates the development of opiate-induced antinociceptive tolerance in mice. J. Clin. Invest. 117 (2007), 3530–3539.
11. [11] Muscoli, C., Doyle, T., Dagostino, C., Bryant, L., Chen, Z., Watkins, L.R., et al. Counter-regulation of opioid analgesia by glial-derived bioactive sphingolipids. J. Neurosci. 30 (2010), 15400–15408.
12. [12] Lauro, F., Giancotti, L.A., Ilari, S., Dagostino, C., Gliozzi, M., Morabito, C., et al. Inhibition of spinal oxidative stress by bergamot polyphenolic fraction attenuates the development of morphine induced tolerance and hyperalgesia in mice. PLoS One, 11, 2016, e0156039.
13. [13] Lauro, F., Ilari, S., Giancotti, L.A., Morabito, C., Malafoglia, V., Gliozzi, M., Palma, E., Salvemini, D., Muscoli, C., The protective role of bergamot polyphenolic fraction on several animal models of pain. Pharmanutrition, 2016.
14. [14] Muscoli, C., Mollace, V., Wheatley, J., Masini, E., Ndengele, M.M., Wang, Z.Q., et al. Superoxide-mediated nitration of spinal manganese superoxide dismutase: a novel pathway in N-methyl-D-aspartate-mediated hyperalgesia. Pain 111 (2004), 96–110.
15. [15] Ndengele, M.M., Cuzzocrea, S., Masini, E., Vinci, M.C., Esposito, E., Muscoli, C., et al. Spinal ceramide modulates the development of morphine antinociceptive tolerance via peroxynitrite-mediated nitroxidative stress and neuroimmune activation. J. Pharmacol. Exp. Ther. 329 (2009), 64–75.
16. [16] Chen, Z., Muscoli, C., Doyle, T., Bryant, L., Cuzzocrea, S., Mollace, V., et al. NMDA-receptor activation and nitroxidative regulation of the glutamatergic pathway during nociceptive processing. Pain 149 (2010), 100–106.
17. [17] Swamy, M., Sirajudeen, K.N., Chandran, G., Nitric oxide (NO), citrulline-NO cycle enzymes, glutamine synthetase, and oxidative status in kainic acid-mediated excitotoxicity in rat brain. Drug Chem. Toxicol. 32 (2009), 326–331.
18. [18] Muscoli, C., Cuzzocrea, S., Riley, D.P., Zweier, J.L., Thiemermann, C., Wang, Z.Q., et al. On the selectivity of superoxide dismutase mimetics and its importance in pharmacological studies. Br. J. Pharmacol. 140 (2003), 445–460.
19. [19] Muscoli, C., Fresta, M., Cardile, V., Palumbo, M., Renis, M., Puglisi, G., et al. Ethanol-induced injury in rat primary cortical astrocytes involves oxidative stress: effect of idebenone. Neurosci. Lett. 329 (2002), 21–24.
20. [20] Voronkova, K.V., Meleshkov, M.N., Use of Noben (idebenone) in the treatment of dementia and memory impairments without dementia. Neurosci. Behav. Physiol. 39 (2009), 501–506.
21. [21] Buyse, G.M., Voit, T., Schara, U., Straathof, C.S., D'Angelo, M.G., Bernert, G., Cuisset, J.M., Finkel, R.S., Goemans, N., McDonald, C.M., Rummey, C., Meier, T., DELOS Study Group, Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial. Lancet 385 (2015), 1748–1757.
22. [22] Carbone, C., Pignatello, R., Musumeci, C., Puglisi, G., Chemical and technological delivery system of idebenone: a rewiev of literature production. Expert Opin. Drug Deliv. 9 (2012), 1377–1392.
23. [23] Quintans-Júnior, L.J., Barreto, R.S., Menezes, P.P., Almeida, J.R., Viana, A.F., Oliveira, R.C., et al. β-Cyclodextrin-complexed (−)-linalool produces antinociceptive effect superior to that of (−)-linalool in experimental pain protocols. Basic Clin. Pharmacol. Toxicol. 113 (2013), 167–172.
24. [24] Lavoine, N., Tabary, N., Desloges, I., Martel, B., Bras, J., Controlled release of chlorhexidine digluconate using β-cyclodextrin and microfibrillated cellulose. Colloids Surf. B Biointerfaces 121 (2014), 196–205.
25. [25] E.M. martin del valle, cyclodextrins and their uses: a review. Process Biochem. 39 (2004), 1033–1046.
26. [26] Kurkov, S.V., Loftsson, T., Cyclodextrins. Int. J. Pharm. 453 (2013), 167–180.
27. [27] Cannavà, C., Crupi, V., Guardo, M., Majolino, D., Stancanelli, R., Tommasini, S., Ventura, C.A., Venuti, V., Phase solubility and FTIR-ATR studies of idebenone/sulfobutyl ether β-cyclodextrin inclusion complex. J. Inclusion Phenom. Macrocyclic. Chem. 75 (2013), 255–262.
28. [28] Salvemini, D., Wang, Z.Q., Wyatt, P., Bourdon, D.M., Marino, M.H., Manning, P.T., et al. Nitric oxide: a key mediator in the early and late phase of carrageenan induced rat paw. Br. J. Pharmacol. 118 (1996), 829–838.
29. [29] Parkinson, M.H., Schulz, J.B., Giunti, P., Co-enzyme Q10 and idebenone use in Friedreich's ataxia. J. Neurochem. 126:Suppl. 1 (2013), 125–141.
30. [30] Hargreaves, K., Dubner, R., Brown, F., Flores, C., Joris, J., A new and sensitive method for measuring thermal nociception in cutanouse hyperalgesia. Pain 32 (1988), 77–88.
31. [31] Wang, Z.Q., Porreca, F., Cuzzocrea, S., Galen, K., Lightfoot, R., Masini, E., et al. A newly identified role for superoxide in inflammatory pain. J. Pharmacol. Exp. Ther. 309 (2004), 869–878.
32. [32] Manchope, M.F., Calixto-Campos, C., Coelho-Silva, L., Zarpelon, A.C., Pinho-Ribeiro, F.A., Georgetti, S.R., et al. Naringenin inhibits superoxide anion-Induced inflammatory pain: role of oxidative stress, cytokines, nrf-2 and the NO-cGMP-PKG-KATPChannel signaling pathway. PLoS One, 11, 2016, e0153015.
33. [33] Takagi, N., Logan, R., Teves, L., Wallace, M.C., Gurd, J.W., Altered interaction between PSD-95 and the NMDA receptor following transient global Ischemia. J. Neurochem. 74 (2000), 169–178.
34. [34] Salvemini, D., Wang, Z.Q., Zweier, J.L., Samouilov, A., Macarthur, H., Misko, T.P., et al. A nonpeptidyl mimic of superoxide dismutase with therapeutic activity in rats. Science (Wash. DC) 286 (1999), 304–306.
35. [35] Miriyala, S., Spasojevic, I., Tovmasyan, A., Salvemini, D., Vujaskovic, Z., Clair, D. St., Batinic-Haberle, I., Manganese superoxide dismutase, MnSOD and its mimics. Biochim. Biophys. Acta 1822:May (2012) (2012), 794–814.
36. [36] Salvemini, D., Wang, Z.Q., Stern, M.K., Currie, M.G., Misko, T.P., Peroxynitrite decomposition catalysts: therapeutics for peroxynitrite-mediated pathology. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 2659–2663.
37. [37] Doyle1, T., Chen, Z., Muscoli, C., Bryant, L., Esposito, E., Cuzzocrea, S., et al. Targeting the overproduction of peroxynitrite for the prevention and reversal of paclitaxel-induced neuropathic pain. J. Neurosci. 32 (2012), 6149–6160.
38. [38] Batinić-Haberle, I., Rebouças, J.S., Spasojević, I., Superoxide dismutase mimics: chemistry, pharmacology, and therapeutic potential. Antioxid. Redox Signal. 13 (2010), 877–918.
39. [39] Yamakura, F., Taka, H., Fujimura, T., Murayama, K., Inactivation of human manganese-superoxide dismutase by peroxynitrite is caused by exclusive nitration of tyrosine 34–3-nitrotyrosine. J. Biol. Chem. 5:273 (1998), 14085–14089.
40. [40] Gunaydin, H., Houk, K.N., Mechanisms of peroxynitrite-mediated nitration of tyrosine. Chem. Res. Toxicol. 22 (2009), 894–898.
41. [41] Macmillan-Crow, L.A., Cruthirds, D.L., Invited review: manganese superoxide dismutase in disease. Free Radic. Res. 34 (2001), 325–336.
42. [42] Chang, L., Hai-Meng, Z., The role of manganese superoxide dismutase in inflammation defense. Enzyme Res., 2011, 2011, 387176.
43. [43] Flor, H., Turk, D.C., Chronic Pain. An Integrated Biobehavioral Approach. 2011, IASP Press, Seattle.
44. [44] Xu, Z.Z., Zhang, L., Liu, T., Park, J.Y., Berta, T., Yang, R., Serhan, C.N., Ji, R.R., Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat. Med. 16:May (5) (2010), 592–597.
45. [45] Medzhitov, R., Inflammation: new adventures of an old flame. Cell 140 (2010), 771–776.
46. [46] Medzhitov, R., Origin and physiological roles of inflammation. Nature 454 (2008), 428–435.
47. [47] Uttara, B., Singh, A.V., Zamboni, P., Mahajan, R.T., Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr. Neuropharmacol. 7 (2009), 65–74.
48. [48] Abbas, S.S., Schaalan, M.F., Bahgat, A.K., El-Denshary, E.S., Possible potentiation by certain antioxidants of the anti-inflammatory effects of diclofenac in rats. Sci. World J., 2014, 10.1155/2014/731462.
49. [49] No authors listed, Idebenone-Monograph. Altern. Med. Rev. 6 (2001), 83–86.
50. [50] Puglisi, G., Ventura, C.A., Fresta, M., Vandelli, M.A., Cavallaro, G., Zappalà, M., Preparation and physico-chemical study of inclusion complexs between idebenone and modified β-cyclodextrins. J. Inclusion Phenom. Mol. Recognit. Chem. 24 (1996), 193–210.
51. [51] Uekama, K., Hirayama, F., Methods of investigating and preparing inclusion compounds. Duchene, D., (eds.) Cyclodextrins and Their Industrial Uses, 1987, Editions de Santé, Paris, France, 131–172.